Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases

Clinical Rheumatology

Volumn 33, Issue 3, 2014, Pages 329-333

  Kádár, Gabriella ^a   Balázs, Erika ^a   Soós, Boglárka ^b   Laduver, Anita ^c   Keszthelyi, Péter ^c   Szekanecz, Zoltán ^b   Kovács, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c Pandy Kalman Bekes County Hospital   (Hungary)

Author keywords

Ankylosing spondylitis; Biological therapy; Discontinuation; Low disease activity; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BIOLOGICAL THERAPY; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAMILY PLANNING; FOLLOW UP; HUMAN; HUNGARY; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NEOPLASM; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RECURRENT INFECTION; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84896495821     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2508-3     Document Type: Article

References (13)

1. Smolen JS, Robert Landewé R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975
2. Saleem B, Keen H, Goeb Vet al (2010) Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 69:1636-1642
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 58(2 Suppl):S126-S135
4. Quinn MA, Conaghan PG, O'Connor PJ et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo controlled trial. Arthritis Rheum 52:27-35 (Pubitemid 40129229)
5. van den Broek M, Klarenbeek NB, Dirven L et al (2011) Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 70:1389-1394
6. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al (2009) Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 68:914-921
7. Kavanaugh A, Emery P, Fleischmann R, et al (2011) Withdrawal of adalimumab in early rheumatoid arthritis patientswho attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-bind, placebo-controlled trial. ACR 2011, abstract No 1699
8. Tanaka Y, Takeuchi T, Mimori T et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69:1286-1291
9. Tanaka Y, Hirata S, Nawate M, et al (2011) Discontinuation of adalimumab without functional and structural progress after attaining remission in patients with rheumatoid arthritis (an interim report of HONOR study). ACR 2011 abstract No 2468
10. Chimenti MS, Graceffa D, Perricone R (2011) Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 10:636-640
11. Baraliakos X, Listing J, Brandt J et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439-R444
12. Brandt J, Khariouzou A, Listing J et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 44:342-3484
13. Navarro-Compán V, Moreira V, Ariza-Ariza R et al (2011) Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 30:993-996